Issue 04 · The Axes
The Biology Behind the Problem That BPC-157 and TB-500 Target
"The real reason that injury won't heal"
Here's the counterintuitive thing about healing: the tissue itself is usually not the limiting factor.
The fibroblasts that produce collagen are there. The immune cells that clear debris are there. The satellite cells that repair muscle are there. What's often inadequate is the blood supply to deliver them — and the blood supply to remove cellular waste so the repair environment stays functional.
The name for new blood vessel growth is angiogenesis. And it is the central bottleneck in tissue repair.
When you injure tissue, blood supply to the damaged area is compromised. Cells in that oxygen-deprived zone release molecular distress signals that trigger VEGF (Vascular Endothelial Growth Factor) — the "build blood vessels here" signal. VEGF activates endothelial cells to migrate, proliferate, and form new capillary networks. Once those networks establish, nutrient delivery is restored and repair can proceed.
Without adequate angiogenesis, healing stalls. The tissue fills with disorganized scar rather than regenerating functional architecture. This is the mechanism behind chronic tendon injuries: not that they fail to heal at all, but that they get stuck partway — adequate blood supply to reduce acute inflammation but not enough to complete the structural repair.
The angiogenic capacity of the body declines meaningfully with age. Every component of the cascade degrades:
VEGF production falls. Older tissue produces a quieter distress signal in response to hypoxia. The message to "build vessels here" is there — it's just not as loud.
Endothelial cells become less responsive. The cells that need to migrate and form new vessels move more slowly. Endothelial dysfunction — partially driven by cardiovascular risk factors that accumulate with age — compounds this.
Nitric oxide (NO) bioavailability drops. The enzyme that produces NO (eNOS) becomes less active with age. NO is a critical pro-angiogenic signal: it drives vasodilation, activates endothelial cell migration, and amplifies the VEGF response. Lower NO means weaker angiogenic signaling.
Collagen organization degrades. Even when repair happens, the remodeling machinery shifts toward scar over functional tissue. Advanced glycation end-products accumulate in connective tissue, cross-linking collagen in ways that reduce elasticity and resilience.
The net result: the injury that a 28-year-old recovers from in four weeks takes a 48-year-old four months — or never fully resolves. This isn't a character failing. The biological environment for healing is genuinely less capable.
BPC-157 targets the angiogenic bottleneck directly.
It activates eNOS — the enzyme that produces nitric oxide. More eNOS activity means more NO. More NO means vasodilation, stronger endothelial cell activation, and amplified VEGF signaling. The result is a more robust angiogenic response: more blood vessels growing into the injury site, faster.
BPC-157 also directly stimulates tendon fibroblasts — the cells that produce collagen — to migrate and proliferate. It doesn't just increase blood supply; it activates the workers alongside the supply line.
This is why BPC-157 shows effects across such different tissue types in the research: tendon, ligament, muscle, gut lining, nerve, even cornea. The NO/VEGF mechanism is not tissue-specific. It's a universal repair accelerator that happens to be relevant wherever angiogenesis is the bottleneck.
The evidence is mostly rodent data — extensive, from multiple labs, spanning four decades of Sikiric group research. Human trial data is limited. The mechanism is credible and consistent with observed community results. This is the evidence level it is — strong mechanistic + animal, limited human — and you should hold that clearly.
BPC-157 is the signal. TB-500 (Thymosin Beta-4 fragment) is the logistics.
Growing new blood vessels requires endothelial cells to move — to migrate through tissue toward the injury signal. That migration depends on precise regulation of actin, the protein that gives cells their movement capacity. TB-500 modulates actin dynamics, enabling endothelial cells to migrate more efficiently to where they're needed.
TB-500 also downregulates NF-κB — the primary driver of pro-inflammatory signaling — which helps move the healing environment from the destructive inflammatory phase into the constructive proliferative phase.
Together: BPC-157 amplifies the angiogenic signal and activates the collagen producers. TB-500 moves the construction crew to the site and reduces inflammatory interference. They target different rate-limiting steps in the same process.
The practical stack: 250–500 mcg BPC-157 once or twice daily, 2–2.5 mg TB-500 two to three times per week, for a 4–6 week loading phase. Most users report noticeable reduction in acute inflammation within 1–2 weeks, meaningful pain and mobility improvement by weeks 3–4, and continued structural improvement through weeks 6–8.
This is important to say clearly: peptides don't replace rehabilitation.
Collagen organizes in the direction of mechanical stress. You can accelerate the healing process with BPC-157 and TB-500, but the structural repair still needs appropriate loading to organize correctly. The injury that resolves with peptides alone and no movement work tends to come back. The injury that pairs peptide support with progressive loading actually heals.
These are tools that improve the biological environment for repair. The repair still requires the right mechanical inputs.
We'll go deep on aging itself — what's actually happening at the cellular level, the 12 hallmarks of aging framework, and how that maps to the longevity peptides. It's the most intellectually dense issue I'll write, and also the one I find most useful for understanding why the longevity stack is what it is.